AtriCure (NASDAQ:ATRC) Director Sven Wehrwein Sells 4,967 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 4,967 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $38.00, for a total transaction of $188,746.00. Following the completion of the sale, the director directly owned 34,374 shares in the company, valued at $1,306,212. This represents a 12.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Sven Wehrwein also recently made the following trade(s):

• On Monday, November 24th, Sven Wehrwein sold 5,033 shares of AtriCure stock. The stock was sold at an average price of $37.32, for a total transaction of $187,831.56.

AtriCure Stock Down 6.4%

Shares of ATRC opened at $36.03 on Thursday. AtriCure, Inc. has a fifty-two week low of $28.29 and a fifty-two week high of $43.11. The company’s fifty day moving average is $35.14 and its two-hundred day moving average is $34.22. The firm has a market cap of $1.79 billion, a PE ratio of -59.06 and a beta of 1.56. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $134.27 million for the quarter, compared to analysts’ expectations of $131.25 million. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The firm’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On AtriCure

A number of hedge funds have recently modified their holdings of ATRC. Envestnet Asset Management Inc. raised its holdings in shares of AtriCure by 22.9% during the first quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock valued at $1,828,000 after acquiring an additional 10,570 shares during the period. CWM LLC increased its stake in shares of AtriCure by 46.2% during the 1st quarter. CWM LLC now owns 2,818 shares of the medical device company’s stock worth $91,000 after purchasing an additional 891 shares during the last quarter. Victory Capital Management Inc. bought a new position in AtriCure during the first quarter valued at about $1,847,000. Allianz Asset Management GmbH lifted its holdings in AtriCure by 22.8% in the 1st quarter. Allianz Asset Management GmbH now owns 122,858 shares of the medical device company’s stock worth $3,963,000 after purchasing an additional 22,838 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of AtriCure during the 1st quarter worth $2,926,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on ATRC. Wall Street Zen upgraded AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. Needham & Company LLC lifted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, July 30th. BTIG Research set a $54.00 price target on AtriCure in a research report on Wednesday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $52.22.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.